Skip to main content

Table 4 Confounding factors that influence the recurrence prevention effectiveness of the c.1562A > C SNV in PINK1

From: PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study

 

Recurrence (n = 27)

Non-recurrence (n = 57)

p-value

PINK1

 c.1562C (n = 43) (%)

8 (29.6)

35 (61.4)

0.01

 c.1562A (n = 41) (%)

19 (70.4)

22 (38.6)

 

Pathological histotype

  

0.99

 Non poor (%)

18 (66.7)

33 (57.9)

 

 Poor (%)

9 (33.3)

24 (42.1)

 

Location

  

0.42

 Right (%)

7 (25.9)

19 (33.3)

 

 Left (%)

20 (74.1)

38 (66.7)

 

Depth

  

0.55

  < T4 (%)

20 (74.1)

49 (86.0)

 

  ≥ T4 (%)

7 (25.9)

8 (14.0)

 

Stage

  

0.4

 II (%)

5 (18.5)

4 (7.0)

 

 III (%)

22 (81.5)

53 (93.0)

 

Adjuvant regimena

  

0.96

 Oxaliplatin combination (%)

8 (29.6)

13 (22.8)

 

 Others (%)

19 (70.4)

44 (77.2)

 
  1. Logistic regression was performed to test for confounding effects on the relationship between a PINK1 SNV (c.1562A > C) and non-recurrence of CRC
  2. aOxaliplatin combination: FOLFOX (5-FU, levofolinate, oxaliplatin):1, CAPOX (capecitabine, oxaliplatin):18, SOX (S-1, oxaliplatin):1
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us